CHICAGO, July 30,
2024 /PRNewswire/ -- AliveDx, a global in vitro
diagnostics company that aims to transform patient care, today
announced LumiQ™ - an innovative, automated immunofluorescence
assay (IFA) solution. With this portfolio expansion, AliveDx can
offer customers a differentiating, end-to-end [turnkey] solution
for autoimmune diagnostics with LumiQ IFA and groundbreaking
MosaiQ® planar microarray technology.
"The addition of LumiQ is a logical and important step in our
commitment to transform patient care through faster and more
precise diagnosis," stated Manuel O. Méndez, CEO of AliveDx. "Our
customers are looking for partners to support them along the full
autoimmune diagnostic pathway, and IFA is a key step in that
workflow – today we are proud to be able to honour that
commitment."
IFA is recognized as a gold standard for the detection of
anti-nuclear antibodies (ANA) when screening for the presence of
autoimmune diseases.
LumiQ offers laboratories a powerful tool to enhance their
diagnostic capabilities while improving efficiency and reliability.
LumiQ automates every step of the IFA workflow including slide
preparation and image capture in an all-in-one solution that
increases walkaway time. The solution provides recommendations for
a positive and negative classification as well as pattern
interpretation with an excellent level of confidence – aiding
specialists in reading IFA results and contributing to improved
consistency and reduced human error.
MosaiQ, our multiplexed, fully automated planar microarray
platform complements LumiQ for a comprehensive autoimmune diagnosis
and vice versa. Both platforms offer high-throughput and automation
to address the growing expectations for laboratory efficiency.
About AliveDx
At AliveDx, our mission is to empower
diagnostic insights, transform patient care, and innovate for life.
With over 30 years in in-vitro diagnostics, we aim to advance the
future of diagnostics worldwide. We prioritize the health of
patients and create innovative solutions that enable laboratories
and clinicians to shorten the time to diagnosis. Our brands aim to
create both economical and clinical value. We achieve this by
simplifying laboratory workflows and delivering fast and accurate
results that streamline clinical decision-making. At AliveDx, we
innovate for life. We collaborate with laboratorians, clinicians,
patient advocacy groups, academic institutions, and industry
partners. When we feel 'alive', we do more than just live. Feeling
alive is giving purpose, meaning and energy to our communities, our
work and ourselves.
About the MosaiQ platform
MosaiQ® is a
fully automated high-throughput platform that streamlines multiplex
testing for Autoimmune, Allergy, and beyond. This intuitive
platform delivers fast and accurate results using advanced
microarray panels to rapidly detect and identify disease
markers—maximizing workflow efficiencies, simplifying pathways, and
helping shorten time to diagnosis.
For more information about AliveDx and its IVD solutions, please
visit www.alivedx.com or connect with us on LinkedIn and
X.
©AliveDx Suisse SA. 2024. The AliveDx logo, AliveDx, MosaiQ and
LumiQ are trademarks or registered trademarks of AliveDx group
companies in various jurisdictions. Menus and capabilities are
subject to change. Not all methods may be available in all
territories. Subject to regulatory clearance.
View original
content:https://www.prnewswire.com/news-releases/alivedx-announces-turnkey-solution-for-precise-automated-autoimmune-diagnostics-302209672.html
SOURCE AliveDx